Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection

Yahong SUN; Xiaoyu YANG; Rui ZHENG

doi:10.12259/j.issn.2095-610X.S20250621

Volume 46 Issue 6

Jun. 2025

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > 46(6): 163-170

Yahong SUN, Xiaoyu YANG, Rui ZHENG. Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection[J]. Journal of Kunming Medical University, 2025, 46(6): 163-170. doi: 10.12259/j.issn.2095-610X.S20250621

Citation:

Yahong SUN, Xiaoyu YANG, Rui ZHENG. Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection[J]. Journal of Kunming Medical University, 2025, 46(6): 163-170. doi: 10.12259/j.issn.2095-610X.S20250621

Citation:

PDF( 1076 KB)

Progress and Challenges in the Study of Bacteriophage Therapy for Carbapenem-Resistant Klebsiella Pneumoniae Infection

doi: 10.12259/j.issn.2095-610X.S20250621

1.
Medical school，Kunming University of Science and Technology，Kunming Yunnan 650500
2.
Regenerative Medicine Research Center
3.
Department of Laboratory Medicine，The First People’s Hospital of Yunnan Province，Kunming Yunnan 650032，China

Received Date: 2024-12-07
Publish Date: 2025-06-25

Abstract

Abstract

Carbapenem-resistant Klebsiella pneumoniae （CRKP） , as a superbug pathogen, has become a critical global public health threat, with significantly increased detection rates especially in ICU and immunocompromised patients. Traditional antibiotics are progressively losing efficacy, and CRKP's antibiotic resistance spectrum continues to expand, presenting enormous clinical treatment challenges. Bacteriophages, as viruses specifically infecting bacteria, have emerged as a new therapeutic strategy for alternative or complementary antibiotic treatment due to their strong lytic capabilities, excellent biofilm penetration, low side effects, and ability to synergize with antibiotics. This article systematically reviews the epidemiology and resistance mechanisms of CRKP, principles and mechanisms of bacteriophage therapy, research progress （including in vitro experiments, animal models, and clinical applications）, combined therapies, and their advantages and challenges. By incorporating the latest research, the article also proposes future development directions, including constructing genetically engineered bacteriophages, designing "intelligent bacteriophages" through synthetic biology, and establishing clinical regulatory systems. Bacteriophage therapy offers a potential breakthrough in combating CRKP, but its standardization, broad-spectrum applicability, and clinical translation pathways still require in-depth exploration and standardization.
- Carbapenem-resistant Klebsiella pneumoniae,
- Antibiotic,
- Bacteriophage,
- Bacteriophage therapy

FullText(HTML)

References(53)

References

[1]	Chen Q,Wang M,Han M,et al. Molecular basis of Klebsiella pneumoniae colonization in host[J]. Microbial Pathogenesis,2023,177:106026. doi: 10.1016/j.micpath.2023.106026
[2]	李海源. 肺炎克雷伯菌乳房炎的致病机理及其耐药性分析[J]. 中国乳业,2023,(11):39-44. doi: 10.12377/1671-4393.23.11.08
[3]	Han Y L,Wen X H,Zhao W,et al. Epidemiological characteristics and molecular evolution mechanisms of carbapenem-resistant hypervirulent Klebsiella pneumoniae[J]. Frontiers in Microbiology,2022,13:1003783. doi: 10.3389/fmicb.2022.1003783
[4]	Śliwka P,Ochocka M,Skaradzińska A. Applications of bacteriophages against intracellular bacteria[J]. Critical Reviews in Microbiology,2021,48(2):222-239.
[5]	Dunne M,Rupf B,Tala M,et al. Reprogramming bacteriophage host range through structure-guided design of chimeric receptor binding proteins [J]. Cell Reports,2019,29(5): 1336-1350. e4.
[6]	Zurabov F,Zhilenkov E. Characterization of four virulent Klebsiella pneumoniae bacteriophages,and evaluation of their potential use in complex phage preparation[J]. Virology Journal,2021,18(1):9. doi: 10.1186/s12985-020-01485-w
[7]	周彤,周秀娟,龙坤兰,等. 肺炎克雷伯菌生物膜治疗的研究进展[J]. 中国抗生素杂志,2023,48:636-642. doi: 10.3969/j.issn.1001-8689.2023.06.005
[8]	Olsen I. Biofilm-specific antibiotic tolerance and resistance[J]. European Journal of Clinical Microbiology & Infectious Diseases,2015,34(5):877-886.
[9]	郭燕,胡付品,朱德妹,等. 2023年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志,2024,24(6):627-637.
[10]	Hu F,Pan Y,Li H,et al. Carbapenem-resistant Klebsiella pneumoniae capsular types,antibiotic resistance and virulence factors in China: A longitudinal,multi-centre study[J]. Nat Microbiol,2024,9(3):814-829. doi: 10.1038/s41564-024-01612-1
[11]	Yang X,Sun Q,Li J,et al. Molecular epidemiology of carbapenem-resistant hypervirulent Klebsiella pneumoniae in China[J]. Emerging Microbes & Infections,2022,11(1):841-849.
[12]	Zhang R,Liu L,Zhou H,et al. Nationwide surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) strains in China[J]. EBioMedicine,2017,19:98-106. doi: 10.1016/j.ebiom.2017.04.032
[13]	Conlan S,Thomas P J,Deming C,et al. Single-molecule sequencing to track plasmid diversity of hospital-associated carbapenemase-producing Enterobacteriaceae[J]. Science Translational Medicine,2014,6(254):254ra126.
[14]	Pu D,Zhao J,Chang K,et al. "Superbugs" with hypervirulence and carbapenem resistance in Klebsiella pneumoniae: the rise of such emerging nosocomial pathogens in China[J]. Science Bulletin,2023,68(21):2658-2670. doi: 10.1016/j.scib.2023.09.040
[15]	Strathdee S A,Hatfull G F,Mutalik V K,et al. Phage therapy: From biological mechanisms to future directions[J]. Cell,2023,186(1):17-31. doi: 10.1016/j.cell.2022.11.017
[16]	Toporek A,Lechtzin N. Viruses to the rescue-Use of bacteriophage to treat resistant pulmonary infections[J]. Cell,2022,185(11):1807-1808. doi: 10.1016/j.cell.2022.04.037
[17]	Hu B,Margolin W,Molineux I J,et al. The bacteriophage t7 virion undergoes extensive structural remodeling during infection[J]. Science,2013,339(6119):576-579. doi: 10.1126/science.1231887
[18]	Tzipilevich E,Habusha M,Ben-Yehuda S. Acquisition of phage sensitivity by bacteria through exchange of phage receptors [J]. Cell,2017,168(1-2): 186-199. e12.
[19]	Federici S,Nobs S P,Elinav E. Phages and their potential to modulate the microbiome and immunity[J]. Cellular & Molecular Immunology,2021,18(4):889-904.
[20]	Karygianni L,Ren Z,Koo H,et al. Biofilm matrixome: Extracellular components in structured microbial communities[J]. Trends in Microbiology,2020,28(8):668-681. doi: 10.1016/j.tim.2020.03.016
[21]	Gordon M,Ramirez P. Efficacy and experience of bacteriophages in biofilm-related infections[J]. Antibiotics (Basel,Switzerland),2024,13(2):125. doi: 10.3390/antibiotics13020125
[22]	Tkhilaishvili T,Winkler T,Müller M,et al. Bacteriophages as adjuvant to antibiotics for the treatment of periprosthetic joint infection caused by multidrug-resistant pseudomonas aeruginosa[J]. Antimicrobial Agents and Chemotherapy,2019,64(1):e00924-19.
[23]	Ferry T,Leboucher G,Fevre C,et al. Salvage Debridement,Antibiotics and Implant Retention ("DAIR") with local injection of a selected cocktail of bacteriophages: Is it an option for an elderly patient with relapsing staphylococcus aureus prosthetic-joint infection?[J]. Open Forum Infectious Diseases,2018,5(11):ofy269. doi: 10.1093/ofid/ofy269
[24]	Fang Q,Yin X,He Y,et al. Safety and efficacy of phage application in bacterial decolonisation: A systematic review[J]. The Lancet Microbe,2024,5(5):e489-e499. doi: 10.1016/S2666-5247(24)00002-8
[25]	Guo Z,Liu M,Zhang D. Potential of phage depolymerase for the treatment of bacterial biofilms[J]. Virulence,2023,14(1):2273567. doi: 10.1080/21505594.2023.2273567
[26]	Hossain A A,Pigli Y Z,Baca C F,et al. DNA glycosylases provide antiviral defence in prokaryotes[J]. Nature,2024,629(8011):410-416. doi: 10.1038/s41586-024-07329-9
[27]	Berngruber T W,Lion S,Gandon S. Evolution of suicide as a defence strategy against pathogens in a spatially structured environment[J]. Ecology Letters,2013,16(4):446-453. doi: 10.1111/ele.12064
[28]	Hör J,Wolf S G,Sorek R. Bacteria conjugate ubiquitin-like proteins to interfere with phage assembly[J]. Nature,2024,631(8022):850-856. doi: 10.1038/s41586-024-07616-5
[29]	Reina J,Reina N. Phage therapy,an alternative to antibiotic therapy?[J]. Revista Espanolade Quimioterapia,2018,31(2):101-104.
[30]	Gordillo Altamirano F L,Barr J J. Phage therapy in the postantibiotic era[J]. Clinical Microbiology Reviews,2019,32(2):e00066-18.
[31]	Kebriaei R,Lev K L,Shah R M,et al. Eradication of biofilm-mediated methicillin-resistant staphylococcus aureus infections in vitro: Bacteriophage-antibiotic combination[J]. Microbiology Spectrum,2022,10(2):e0041122. doi: 10.1128/spectrum.00411-22
[32]	Zhao R,Jiang S,Ren S,et al. A novel phage putative depolymerase,Depo16,has specific activity against K1 capsular-type Klebsiella pneumoniae[J]. Applied and Environmental Microbiology,2024,90(4):e0119723. doi: 10.1128/aem.01197-23
[33]	Taha O A,Connerton P L,Connerton I F,et al. Bacteriophage ZCKP1: A potential treatment for Klebsiella pneumoniae isolated from diabetic foot patients[J]. Frontiers in Microbiology,2018,9:2127. doi: 10.3389/fmicb.2018.02127
[34]	Federici S,Kredo-Russo S,Valdés-Mas R,et al. Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation [J]. Cell,2022,185(16): 2879-2898. e24.
[35]	Gan L,Feng Y,Du B,et al. Bacteriophage targeting microbiota alleviates non-alcoholic fatty liver disease induced by high alcohol-producing Klebsiella pneumoniae[J]. Nat Commun,2023,14(1):3215. doi: 10.1038/s41467-023-39028-w
[36]	Cui X,Du B,Feng J,et al. A novel phage carrying capsule depolymerase effectively relieves pneumonia caused by multidrug-resistant Klebsiella aerogenes[J]. Journal of Biomedical Science,2023,30(1):75. doi: 10.1186/s12929-023-00946-y
[37]	Cano E J,Caflisch K M,Bollyky P L,et al. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: Case report and in vitro characterization of anti-biofilm activity[J]. Clinical Infectious Diseases,2021,73(1):e144-e151. doi: 10.1093/cid/ciaa705
[38]	Le T,Nang S C,Zhao J,et al. Therapeutic potential of intravenous phage as stand alone therapy for recurrent drug-resistant urinary tract infections[J]. Antimicrobial Agents and Chemotherapy,2023,67(4):e0003723. doi: 10.1128/aac.00037-23
[39]	Shi Y,Zhang W,Li L,et al. Evaluation of phage-based decontamination in respiratory intensive care unit environments using ddPCR and 16S rRNA targeted sequencing techniques[J]. Frontiers in Cellular and Infection Microbiology,2024,14:1442062. doi: 10.3389/fcimb.2024.1442062
[40]	Eskenazi A,Lood C,Wubbolts J,et al. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae[J]. Nat Commun,2022,13(1):302. doi: 10.1038/s41467-021-27656-z
[41]	Volozhantsev N V,Borzilov A I,Shpirt A M,et al. Comparison of the therapeutic potential of bacteriophage KpV74 and phage-derived depolymerase (β-glucosidase) against Klebsiella pneumoniae capsular type K2[J]. Virus Research,2022,322:198951. doi: 10.1016/j.virusres.2022.198951
[42]	Yang P,Shan B,Hu X,et al. Identification of a novel phage depolymerase against ST11 K64 carbapenem-resistant Klebsiella pneumoniae and its therapeutic potential[J]. Journal of Bacteriology,2025,207(4):e0038724. doi: 10.1128/jb.00387-24
[43]	姜昕宇,吴楠楠,卢曙光,等. 噬菌体临床应用监管法规的现状及展望[J]. 中国抗生素杂志,2024,49(1):26-34. doi: 10.3969/j.issn.1001-8689.2024.01.003
[44]	Taati Moghadam M,Amirmozafari N,Shariati A,et al. How phages overcome the challenges of drug resistant bacteria in clinical infections[J]. Infection and Drug Resistance,2020,13:45-61. doi: 10.2147/IDR.S234353
[45]	Chakraborty S,Rohit A,Prasanthi S J,et al. A New casjensviridae bacteriophage isolated from hospital sewage for inactivation of biofilms of carbapenem resistant Klebsiella pneumoniae clinical isolates[J]. Pharmaceutics,2024,16(7):904. doi: 10.3390/pharmaceutics16070904
[46]	Hibstu Z,Belew H,Akelew Y,et al. Phage therapy: A different approach to fight bacterial infections [J]. Biologics : Targets & Therapy,2022,16: 173-186.
[47]	Liu D,Van Belleghem J D,de Vries C R,et al. The safety and toxicity of phage therapy: A review of animal and clinical studies[J]. Viruses,2021,13(7):1268. doi: 10.3390/v13071268
[48]	Dedrick R M,Guerrero-Bustamante C A,Garlena R A,et al. Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant mycobacterium abscessus[J]. Nature Medicine,2019,25(5):730-733. doi: 10.1038/s41591-019-0437-z
[49]	Kortright K E,Chan B K,Koff J L,et al. Phage therapy: A renewed approach to combat antibiotic-resistant bacteria[J]. Cell Host & Microbe,2019,25(2):219-232.
[50]	Ando H,Lemire S,Pires D P,et al. Engineering modular viral scaffolds for targeted bacterial population editing[J]. Cell Systems,2015,1(3):187-196. doi: 10.1016/j.cels.2015.08.013
[51]	Kilcher S,Studer P,Muessner C,et al. Cross-genus rebooting of custom-made,synthetic bacteriophage genomes in L-form bacteria[J]. Proceedings of the National Academy of Sciences of the United States of America,2018,115(3):567-572.
[52]	Schooley R T,Biswas B,Gill J J,et al. Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection[J]. Antimicrobial Agents and Chemotherapy,2017,61(10):e00954-17.
[53]	Letkiewicz S,Łusiak-Szelachowska M,Międzybrodzki R,et al. Low immunogenicity of intravesical phage therapy for urogenitary tract infections[J]. Antibiotics (Basel,Switzerland),2021,10(6):627. doi: 10.3390/antibiotics10060627

Relative Articles(20)

Relative Articles

[1]	Hao HUANG, Xuelin LI, Zehua HAN, Lin CHANG, Pengfei ZHU, Yingying XIANG. Application of Bacteriophages in Common Infectious Diseases of the Oral Cavity. Journal of Kunming Medical University, 2025, 46(1): 148-153. doi: 10.12259/j.issn.2095-610X.S20250122
[2]	Xuelin LI, Xiaoyan YANG, Zehua HAN, Yuliang CHEN, Xingyuan XU, Chunyan ZHANG, Yingying XIANG. Synergistic Mechanisms and Applications of Phage-Antibiotic Combination Therapy. Journal of Kunming Medical University, 2025, 46(12): 1-8.
[3]	Jie LI, Yuan HE, Chunyan WU, Bin SHAN, Rui ZHENG, Zhifu GUAN, Baojun REN, Chunxia SHI, Youquan ZHOU, Hanyu LIU, Mi ZHANG, Yanming KANG, Guibo SONG. Distribution and Drug Resistance Analysis of Bacteria in Sterile Body Fluids in Yunnan from 2017 to 2021. Journal of Kunming Medical University, 2023, 44(3): 61-67. doi: 10.12259/j.issn.2095-610X.S20230309
[4]	Shaoyou DENG, Yulan ZHAO, Peijin WANG, Rong LI, Jintao LI, Hong ZHENG. Effects of Osteoking Combined with Antibiotic Cocktail on Insulin Resistance and Gut Flora in db/db Mice. Journal of Kunming Medical University, 2023, 44(5): 12-18. doi: 10.12259/j.issn.2095-610X.S20230530
[5]	Rongyu YANG, Fei SONG, Yunlin WEI, Xianghong YANG, Kaiwen Duan, Yingying XIANG. Effects of Different Accumulation Culture Methods on the Titer of Phage PEf771. Journal of Kunming Medical University, 2022, 43(2): 7-11. doi: 10.12259/j.issn.2095-610X.S20220218
[6]	Shu-qi CHEN, Peng ZHAO, Ge-fen YIN, Xia XIAO, Yan LI. Knowledge and Behavior of Antibiotics from the Perspective of One Heath among Senior University Students in Kunming. Journal of Kunming Medical University, 2021, 42(10): 45-50. doi: 10.12259/j.issn.2095-610X.S20211003
[7]	Zheng Zhi Rong , Shao Rui Fei , Zhao Shi Ming , Zhang Yi Xin , Chen Guo Bing . . Journal of Kunming Medical University, 2020, 41(05): 91-95.
[8]	Xiang Ying Ying , Song Fei , Yang Xiang Hong , Zhou Jing , Yu Hong Bin , Wei Yun Lin , Ji Xiu Ling . . Journal of Kunming Medical University, 2020, 41(06): 167-173.
[9]	Yang Mei Jun , Pan Xing , Ye Ji Ming . Analysis on the Detection of Carbapenem-Resistant Klebsiella Pneumonia in a Hospital in Recent 5 Years. Journal of Kunming Medical University, 2018, 39(07): 76-79.
[10]	Yang Hong Yu , Zhao Shi Hao , Zhao Rui , Lv Yu , He Xiao Guang , Peng Yun Zhu , Yin Zhu Ping , Zhang Jing Jing , Lin Yan . The Incidence of Pharyngeal Fistula after Total Laryngectomy and the Dynamic Analysis of Antimicrobial Use. Journal of Kunming Medical University, 2018, 39(04): 70-72.
[11]	Chen Jing Yi , Liao Fei , Feng Lei , Chu Cong Jia . Prevalence and Drug Resistance of Streptococcus Pneumoniae Infection in Children in Yuxi during from 2014 to 2016. Journal of Kunming Medical University, 2017, 38(11): 82-85.
[12]	Su Xue Wen , Zhu Hua , Si Ri Gu Leng , Yuan Hai Feng . Analysis of Antibiotic Use for Bronchial Pneumonia in Pediatrics. Journal of Kunming Medical University, 2017, 38(07): 126-129.
[13]	Zhou Gui . A Multivariate Analysis on the Time of Using Antibiotics for Treating the Ventilator-associated Bacterial Pneumonia. Journal of Kunming Medical University,
[14]	Li Jian Hua . Evaluation of Antimicrobial Efficacy of Local Drug Resistance Spectrum Antibiotics and Foreign Guideline on Community Acquired Pneumonia. Journal of Kunming Medical University,
[15]	Li Xiao Fei . . Journal of Kunming Medical University,
[16]	Wu Gao Li . . Journal of Kunming Medical University,
[17]	Hua Peng . . Journal of Kunming Medical University,
[18]	. Resistance Analysis and Epidemiological Survey of 878 Acinetobacter Baumannii Solates. Journal of Kunming Medical University,
[19]	Chai Yan Ling . The Clinical Effect of YADRAN Tooth Powder Combined with Periodental Non-surgical Treatment on Periodontitis. Journal of Kunming Medical University,
[20]	. . Journal of Kunming Medical University,